Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10382872 | 0.74 | CYP17A1 (0.38) | CCNCCDK8 | |
| SCHEMBL9975865 | 0.71 | KRAS (0.36) | KRASCCNCCDK8NR1I2KCNH2 | |
| SCHEMBL2107411 | 0.67 | AXL (0.36) | NR1I2KCNH2GRM2 | |
| SCHEMBL9975784 | 0.65 | KDM4E (0.44) | KRAS | |
| SCHEMBL9696347 | 0.64 | PRKDC (0.41) | CCNCCDK8 | |
| SCHEMBL16456303 | 0.63 | TNKS (0.56) | KRASNR1I2KCNH2GRM2 | |
| SCHEMBL16456319 | 0.63 | TNKS (0.56) | KRASNR1I2KCNH2GRM2 | |
| SCHEMBL16456394 | 0.63 | TNKS (0.56) | KRASNR1I2KCNH2GRM2 | |
| SCHEMBL6850751 | 0.61 | ADORA2A (0.37) | CCNCCDK8 | |
| SCHEMBL27843011 | 0.61 | CYP2A6 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012083105-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | KRAS 1373/4885CCNC 554/4885CDK8 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.